

Please type a plus sign (+) inside this box

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete If Known

Application Number	10/071,570
Filing Date	February 8, 2002
First Named Inventor	Buser, et al.
Group Art Unit	1614
Examiner Name	To be assigned
Attorney Docket Number	R0134A-REG

Sheet 1 of 1

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
6	A2	5,859,029		Emonds-Alt, et al.	01-12-1999	

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ₆
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
5	B6	WO	99/07677	A1	Eli Lilly & Co. (US)	02-18-1999		
1	B7	WO	99/07681	A1	Eli Lilly & Co. (US)	02-18-1999		
3	B8	WO	00/67742	A2	Warner- Lambert Co. (US)	11-16-2000		
2	B9	EP	1 035 115	A1	F. Hoffman- La Roche AG (CH)	09-13-2000		
9	B10	GB	2 347 422	A	F. Hoffmann- La Roche AG (CH)	09-06-2000		

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²

Examiner
Signature

[Signature]

Date
Considered

7-21-03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231
Doc. #119950v1

Please type a plus sign (+) inside this box

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1049A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 1

Complete If Known

Application Number **10/071,570**
 Filing Date **February 8, 2002**
 First Named Inventor **Buser, et al.**
 Group Art Unit **1614**
 Examiner Name **To be assigned**
 Attorney Docket Number **R0134A-REG**

RECEIVED
 MAY 16 2002

TECH CENTER 1600/29

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
(S)	A1	5,783,562		Shaobo	07-21-1998	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ₆
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
(S)	B1	CA	2,151,113	A1	Eli Lilly & Co., U.S.A.	12-11-1995		
(S)	B2	WO	92/08733	A1	Asta Medica AG, DE	05-29-1992		
(S)	B3	WO	99/59583	A1	Merck & Co., US	11-25-1999		
(S)	B4	WO	00/47221	A1	Nat. Institute of Immunology IN, etc.	08-17-2000		
(S)	B5	WO	01/01922	A2	Innova Ltd., GB	01-11-2001		

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
(S)	C1	SASTRY, B.V. Rama, et al., "Significance of Substance P- and Enkephalin-Peptide Systems in the Male Genital Tract," <i>Annals of the New York Academy of Sciences</i> , (1991), pp. 632,339-353,	
(S)	C2	HOPKINS, Bennet J., et al., "Evidence for Adrenergic and Tachykinin Activity in Venom of the Stonefish (<i>Synanceja Trachynis</i>), <i>Toxicon</i> , (1996), pp. 541-554, vol. 34, no. 5, Pergamon, GB	
(S)	C3	IWAMURA, Masatsugu, et al., "Supprerssion of the growth and invasiveness of human prostate cancer cells in vitro by neuropeptide antagonist substance P analogues," <i>Urologic Oncology</i> , (1998), pp. 24-28, vol. 4, Elsevier	
(S)	C4	BULJUBASICH, Sretna, et al., "An immunohistochemical and pharmacological study of tachykinins in the rate and guinea-pig prostate glands," <i>EJP (Europ. Journal of Pharmacology)</i> , (1999), pp. 137-144, vol. 380, Elsevier	

Examiner
Signature

BT

Date
Considered

7-31-03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231
 Doc. #117407

COPY OF PAPERS
ORIGINALLY FILED